These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 31371483)

  • 1. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D
    Dedic N; Jones PG; Hopkins SC; Lew R; Shao L; Campbell JE; Spear KL; Large TH; Campbell UC; Hanania T; Leahy E; Koblan KS
    J Pharmacol Exp Ther; 2019 Oct; 371(1):1-14. PubMed ID: 31371483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.
    Koblan KS; Kent J; Hopkins SC; Krystal JH; Cheng H; Goldman R; Loebel A
    N Engl J Med; 2020 Apr; 382(16):1497-1506. PubMed ID: 32294346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.
    Newman-Tancredi A; Kleven MS
    Psychopharmacology (Berl); 2011 Aug; 216(4):451-73. PubMed ID: 21394633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856.
    Begni V; Sanson A; Luoni A; Sensini F; Grayson B; Munni S; Neill JC; Riva MA
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.
    Revel FG; Moreau JL; Pouzet B; Mory R; Bradaia A; Buchy D; Metzler V; Chaboz S; Groebke Zbinden K; Galley G; Norcross RD; Tuerck D; Bruns A; Morairty SR; Kilduff TS; Wallace TL; Risterucci C; Wettstein JG; Hoener MC
    Mol Psychiatry; 2013 May; 18(5):543-56. PubMed ID: 22641180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An antipsychotic without dopamine receptor blockade?].
    Spoelstra SK; Bruggeman R; Knegtering H
    Tijdschr Psychiatr; 2021; 63(11):804-809. PubMed ID: 34851520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1/5-HT
    Saarinen M; Mantas I; Flais I; Ågren R; Sahlholm K; Millan MJ; Svenningsson P
    Neuropsychopharmacology; 2022 Dec; 47(13):2319-2329. PubMed ID: 36100653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged reversal of the phencyclidine-induced impairment in novel object recognition by a serotonin (5-HT)1A-dependent mechanism.
    Horiguchi M; Miyauchi M; Neugebauer NM; Oyamada Y; Meltzer HY
    Behav Brain Res; 2016 Mar; 301():132-41. PubMed ID: 26342283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antipsychotics with no dopamine receptor blockade; promise or hype?].
    Vinkers CH
    Ned Tijdschr Geneeskd; 2020 Dec; 164():. PubMed ID: 33332053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.
    Højlund M; Correll CU
    Expert Opin Investig Drugs; 2022 Dec; 31(12):1279-1290. PubMed ID: 36533396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
    Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.
    Depoortère R; Auclair AL; Bardin L; Bruins Slot L; Kleven MS; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):266-77. PubMed ID: 17375085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: role of indirect 5-HT(1A) partial agonism.
    Horiguchi M; Meltzer HY
    Behav Brain Res; 2013 Jun; 247():158-64. PubMed ID: 23538066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blonanserin ameliorates social deficit through dopamine-D
    Takeuchi S; Hida H; Uchida M; Naruse R; Yoshimi A; Kitagaki S; Ozaki N; Noda Y
    Neurochem Int; 2019 Sep; 128():127-134. PubMed ID: 30998952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.
    Depoortère R; Bardin L; Auclair AL; Kleven MS; Prinssen E; Colpaert F; Vacher B; Newman-Tancredi A
    Br J Pharmacol; 2007 May; 151(2):253-65. PubMed ID: 17375086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The serotonin 5-HT₁A receptor agonist tandospirone improves executive function in common marmosets.
    Baba S; Murai T; Nakako T; Enomoto T; Ono M; Shimizu I; Ikeda K
    Behav Brain Res; 2015; 287():120-6. PubMed ID: 25804359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice.
    Rajagopal L; Massey BW; Michael E; Meltzer HY
    Psychopharmacology (Berl); 2016 Feb; 233(4):649-60. PubMed ID: 26558619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multitarget 1,4-Dioxane Compounds Combining Favorable D
    Del Bello F; Ambrosini D; Bonifazi A; Newman AH; Keck TM; Giannella M; Giorgioni G; Piergentili A; Cappellacci L; Cilia A; Franchini S; Quaglia W
    ACS Chem Neurosci; 2019 May; 10(5):2222-2228. PubMed ID: 30609891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine D
    Miyauchi M; Neugebauer NM; Meltzer HY
    J Psychopharmacol; 2017 Apr; 31(4):442-452. PubMed ID: 28347261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.